kokain Tökéletes Tanács atlas acs 2 timi 51 Monet Észlelési Nagyvárosi
atlas acs 2
figure21_large.png
Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet - wikidoc
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary
RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL | Journal of the American College of Cardiology
Unmet Needs in the Secondary Prevention in ACS: The Dual Pathway Approach (Transcript)
PPT - C. Michael Gibson, MS, MD on behalf of the ATLAS ACS 2 TIMI 51 Investigators PowerPoint Presentation - ID:1519803
Factor Xa Inhibitors in Coronary Artery Disease - ppt download
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
figure26_large.png
ATLAS ACS 2-TIMI 51: Statistical Analysis Pre-specified Primary Efficacy Analysis - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51 | tctmd.com
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial - The Lancet
The ATLAS ACS 2-TIMI 51 trial [11] | Download Table
NOACS: Emerging data in ACS/IHD - ppt download
Dia 1
ATLAS ACS-TIMI 46 – TIMI STUDY GROUP
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar